Canada Pension Plan Investment Board acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 161,810 shares of the life sciences company’s stock, valued at approximately $28,451,000. Canada Pension Plan Investment Board owned approximately 0.11% of Illumina at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Elyxium Wealth LLC purchased a new position in shares of Illumina in the 4th quarter worth $25,000. Laurel Wealth Advisors LLC purchased a new stake in shares of Illumina during the 4th quarter valued at about $26,000. Fiduciary Financial Advisors purchased a new stake in shares of Illumina during the 2nd quarter valued at about $26,000. Quarry LP bought a new position in shares of Illumina in the 3rd quarter valued at about $32,000. Finally, Activest Wealth Management lifted its holdings in shares of Illumina by 671.9% in the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 215 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
ILMN has been the topic of several analyst reports. Zacks Research raised Illumina from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 3rd. Guggenheim raised their price objective on Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Stifel Nicolaus lifted their target price on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Evercore reissued an “outperform” rating on shares of Illumina in a research report on Monday, July 6th. Finally, JPMorgan Chase & Co. increased their price target on Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $188.40.
Insider Buying and Selling
In related news, Director Keith A. Meister sold 138,379 shares of the business’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $228.89, for a total transaction of $31,673,569.31. Following the completion of the transaction, the director owned 1,033,910 shares in the company, valued at $236,651,659.90. The trade was a 11.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the transaction, the senior vice president owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 2,034,688 shares of company stock valued at $417,970,281. Insiders own 2.90% of the company’s stock.
More Illumina News
Here are the key news stories impacting Illumina this week:
- Positive Sentiment: Illumina’s second-quarter results showed continued operating momentum, with revenue of approximately $1.16 billion, up about 9.5% year over year, and earnings of $1.31 per share versus the $1.23 consensus estimate. Management also raised full-year revenue and non-GAAP EPS guidance. Should You Add Illumina Stock to Your Portfolio Now?
- Positive Sentiment: Investors continue to point to growth in sequencing, oncology applications and multiomics as potential catalysts for ILMN, although cost volatility could pressure margins. Should You Add Illumina Stock to Your Portfolio Now?
- Neutral Sentiment: Illumina disclosed a new $1.0 billion five-year revolving credit facility, but reported no borrowings outstanding, limiting the immediate balance-sheet implications.
- Neutral Sentiment: Institutional positioning was mixed in the latest quarter, with major investors including FMR, Wellington and JPMorgan adding shares while other funds reduced holdings.
- Negative Sentiment: Director Keith Meister disclosed several sales totaling hundreds of thousands of shares, including 106,543 shares sold for roughly $24.0 million and 138,379 shares sold for approximately $31.7 million. Repeated insider selling can weigh on sentiment, even though it does not necessarily signal deteriorating fundamentals. Insider Selling: Illumina Director Sells 106,543 Shares
- Negative Sentiment: After climbing into the upper $220s and near its 52-week high, ILMN may be experiencing profit-taking. Valuation is also demanding, while reported analyst price targets generally remain below the recent trading level, increasing downside sensitivity if growth expectations cool.
Illumina Stock Performance
Shares of NASDAQ:ILMN opened at $215.59 on Friday. The company has a market capitalization of $32.55 billion, a price-to-earnings ratio of 40.22, a PEG ratio of 3.20 and a beta of 1.45. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $231.81. The firm’s 50-day moving average is $194.05 and its 200 day moving average is $155.60. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53.
Illumina (NASDAQ:ILMN – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the firm earned $1.19 earnings per share. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.
Illumina Profile
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Featured Stories
- Five stocks we like better than Illumina
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
